RBC Europe’s Niagen Bioscience NAGE Stock Holding History

RBC Europe’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-166	Closed	-$797	–	1243
2020 Q4	$797	Hold	166	–	–	﹤0.01%	1097
2020 Q3	$666	Hold	166	–	–	﹤0.01%	1042
2020 Q2	$762	Hold	166	–	–	﹤0.01%	1002
2020 Q1	$541	Hold	166	–	–	﹤0.01%	983
2019 Q4	$715	Hold	166	–	–	﹤0.01%	1002
2019 Q3	$653	Sell	166 -604	-78%	-$2.58K	﹤0.01%	1001
2019 Q2	$3.58K	Hold	770	–	–	﹤0.01%	947
2019 Q1	$3.23K	Hold	770	–	–	﹤0.01%	965
2018 Q4	$2.64K	Hold	770	–	–	﹤0.01%	977
2018 Q3	$3.3K	Hold	770	–	–	﹤0.01%	1004
2018 Q2	$2.86K	Hold	770	–	–	﹤0.01%	1035
2018 Q1	$3.23K	Hold	770	–	–	﹤0.01%	1015
2017 Q4	$4.53K	Buy	770 +604	+364%	+$3.26K	﹤0.01%	969
2017 Q3	$714	Buy	+166	New	+$607	﹤0.01%	1090

Other funds holding NAGE

YRHAM

Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

RBC Europe's NAGE Position: Q1 2021 in Review

RBC Europe sold out of Niagen Bioscience (NAGE) in Q1 2021, closing a stake of 166 shares — an estimated $797 sold.

RBC Europe first reported a position in NAGE in Q3 2017 and held it in 14 quarters. The position peaked at $4.53K in Q4 2017. 96 funds tracked by Wall St. Rank hold NAGE as of Q1 2021.

RBC Europe reported no remaining Niagen Bioscience position as of Q1 2021 after selling out during the quarter.
RBC Europe sold 166 Niagen Bioscience shares in Q1 2021, an estimated $797.
RBC Europe first reported a position in Niagen Bioscience in Q3 2017 and held it in 14 quarters.
RBC Europe's Niagen Bioscience position peaked at $4.53K in Q4 2017.
96 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2021.

Based on RBC Europe's 13F filing for Q1 2021, filed 9 Nov 2023.